Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors

Author(s): Martine Goossens, Katia Pauwels, Nicolas Willemarck, Didier Breyer.

Journal Name: Current Gene Therapy

Volume 13 , Issue 6 , 2013

Submit Manuscript
Submit Proposal

Abstract:

The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need to be considered when performing the risk assessment of a recombinant MVA (rMVA). This paper presents the biosafety issues and the main lessons learned from the evaluation of the clinical trials with rMVA performed in Belgium. Factors such as the specific characteristics of the rMVA, the inserted foreign sequences/transgene, its ability for reconversion, recombination and dissemination in the population and the environment are the main points of attention. Measures to prevent or manage identified risks are also discussed.

Keywords: Biosafety, clinical trials, environmental risk assessment, gene therapy, GMO-based vaccines, MVA-based recombinant vectors.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 6
Year: 2013
Page: [413 - 420]
Pages: 8
DOI: 10.2174/156652321306140103221941

Article Metrics

PDF: 34